Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry

Journal of Clinical Epidemiology

Volumn 66, Issue 8 SUPPL.8, 2013, Pages

  Kane, John M ^a,b,c,d   Kishimoto, Taishiro ^a,e   Correll, Christoph U ^a,b,c,d  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^e KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antipsychotics; Depot; Long acting injection; Mirror image study; Randomized controlled study; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT; PLACEBO; RISPERIDONE;

ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; DATA ANALYSIS; DRUG EFFICACY; GOLD STANDARD; MENTAL DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHIATRY; PSYCHOSIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; SCHIZOPHRENIA; SOCIAL INTERACTION; TIMED DRUG RELEASE;

ANTIPSYCHOTICS; DEPOT; LONG-ACTING INJECTION; MIRROR-IMAGE STUDY; RANDOMIZED CONTROLLED STUDY; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BIAS (EPIDEMIOLOGY); COHORT STUDIES; COMPARATIVE EFFECTIVENESS RESEARCH; DELAYED-ACTION PREPARATIONS; HUMANS; INJECTIONS, INTRAMUSCULAR; MEDICATION ADHERENCE; PATIENT SELECTION; PSYCHIATRY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RESEARCH DESIGN; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84880193278     PISSN: 08954356     EISSN: 18785921     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2013.01.012     Document Type: Article

References (17)

1. S. Leucht, S. Hierl, W. Kissling, M. Dold, and J.M. Davis Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses Br J Psychiatry 200 2012 97 106
2. L. Osterberg, and T. Blaschke Adherence to medication N Engl J Med 353 2005 487 497 (Pubitemid 41127293)
3. S. Keith, and J.M. Kane Partial compliance and patient consequences in schizophrenia: our patients can do better J Clin Psychiatry 64 2003 1308 1315 (Pubitemid 37490235)
4. M. Byerly, R. Fisher, K. Whatley, R. Holland, F. Varghese, and T. Carmody A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia Psychiatry Res 133 2005 129 133 (Pubitemid 40312147)
5. D.I. Velligan, P.J. Weiden, M. Sajatovic, J. Scott, D. Carpenter, R. Ross Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness J Clin Psychiatry 70 Suppl 4 2009 1 46
6. P.J. Perry, B.C. Lund, T. Sanger, and C. Beasley Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial J Clin Psychopharmacol 21 1 2001 14 20 (Pubitemid 32096745)
7. J.M. Kane, and C. Garcia-Ribera Clinical guideline recommendations for antipsychotic long-acting injections Br J Psychiatry Suppl 195 2009 S63 S67
8. P.M. Haddad, M. Taylor, and O.S. Niaz First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies Br J Psychiatry 52 2009 S20 S28
9. R.A. Rosenheck, J.H. Krystal, R. Lew, P.G. Barnett, L. Fiore, D. Valley CSP555 Research Group Long-acting risperidone and oral antipsychotics in unstable schizophrenia N Engl J Med 364 2011 842 851
10. K. Kobak, J.M. Kane, M.E. Thase, and A.A. Nierenberg Why do clinical trials fail? The problem of measurement error in clinical trials: time to test new paradigms? J Clin Psychopharmacol 27 1 2007 1 5 (Pubitemid 46105756)
11. J.M. Kane, and M. Borenstein Compliance in the long-term treatment of schizophrenia Psychopharmacol Bull 21 1 1985 23 27 (Pubitemid 15010867)
12. R.P. John Field experiments: changing group productivity G.M. James, Experiments in social process: a symposium on social psychology 1950 McGraw-Hill New York, NY 82
13. C. Leucht, S. Heres, J.M. Kane, W. Kissling, J.M. Davis, and S. Leucht Oral versus depot antipsychotic drugs for schizophrenia - a critical systematic review and meta-analysis of randomised long-term trials Schizophr Res 127 1-3 2011 83 92
14. Schooler NR, Buckley PF, Mintz J, Goff DC, Kopelowicz A, Lauriello J, et al. PROACTIVE: initial results of an RCT comparing long-acting injectable risperidone to 2nd generation oral antipsychotics. American College of Neuropsychopharmacology 50th annual meeting. Kona, Hawaii, USA; 2011.
15. Kishimoto T. New results alter balance of evidence in meta-analysis on long-acting injectables vs. oral antipsychotics in schizophrenia. Presentation at SIRS, Florence, Italy; 2012.
16. J. Tiihonen, K. Walhbeck, J. Lonnqvist, T. Klaukka, J.P. Ioannidis, and J. Volavka Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study BMJ 333 2006 224
17. J. Tiihonen, J. Haukka, M. Taylor, P.M. Haddad, M.X. Patel, and P. Korhonen A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia Am J Psychiatry 168 6 2011 603 609